Lower Dexamethasone Dose Does Not Impair Survival in Multiple Myeloma
By Elana Gotkine HealthDay Reporter
FRIDAY, Jan. 24, 2025 -- For patients with newly diagnosed multiple myeloma (NDMM) receiving dexamethasone induction, dose reductions do not negatively impact survival, according to a study published online Jan. 2 in Blood.
Rahul Banerjee, M.D., from the Fred Hutchinson Cancer Center in Seattle, and colleagues conducted a secondary pooled analysis of the SWOG 0777 and SWOG 1211 studies, which examined lenalidomide and dexamethasone alone, with or without bortezomib and with or without elotuzumab for NDMM. In all arms, the planned dexamethasone intensity was 40 to 60 mg weekly. Patients were classified as full-dose dexamethasone throughout induction (FD-DEX) or lowered-dose dexamethasone or discontinuation (LD-DEX), permitted for grade 3+ toxicities per both study protocols.
The LD-DEX group included 373 patients (69 percent) of the 541 evaluated. The researchers found that progression-free survival (PFS) and overall survival (OS) did not differ between the FD-DEX and LD-DEX groups. In the multivariate models, predictors of PFS and OS were treatment arm, age 70 years or older, and thrombocytopenia.
"Dexamethasone dose reductions <40 to 60 mg per week are quite common even in the setting of clinical trials," the authors write. "These dose reductions do not appear to negatively impact PFS or OS. We encourage future trials to investigate lowered-dose dexamethasone strategies prospectively, either at treatment onset or within a few cycles of treatment initiation."
Several authors disclosed ties to the biopharmaceutical industry.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted January 2025
Read this next
Annual Whole-Body, Low-Dose CT Aids Management of Smoldering Multiple Myeloma
TUESDAY, April 22, 2025 -- Annual whole-body, low-dose computed tomography (WBLDCT) can improve the management of smoldering multiple myeloma (SMM), according to a study published...
Talquetamab Plus Teclistamab Shows Promise in Multiple Myeloma
THURSDAY, Jan. 9, 2025 -- For patients with relapsed or refractory multiple myeloma, talquetamab plus teclistamab shows response in a high percentage of patients and a higher...
Cilta-Cel Treatment Safe, Effective for Relapsed/Refractory Multiple Myeloma
TUESDAY, Oct. 8, 2024 -- Ciltacabtagene autoleucel (cilta-cel) CAR T-cell therapy for relapsed/refractory multiple myeloma (RRMM) results in a deep and durable response, according...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.